Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Hepatitis

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...

Cirrhosis II: Pathophysiology

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...

Cirrhosis I: Introduction

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...

Viral Hepatitis I: Introduction

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...

Diseases of the Liver and Gallbladder

Diseases of the Liver and Gallbladder

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...

Chronic Pancreatitis II: Pathophysiology

Chronic Pancreatitis II: Pathophysiology

Chronic pancreatitis is a progressive and irreversible inflammation of the pancreas, most often caused by long-term alcohol abuse, but it can also be related to ductal obstruction, smoking, or genetic factors.Chronic pancreatitis occurs when the pancreas is repeatedly exposed to harmful agents like alcohol, smoking, ductal obstruction, or genetic predisposition. These factors lead to the release of toxic metabolites and inflammatory cytokines, sustaining chronic inflammation in the pancreatic...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Efficacy and safety of infliximab in patients with autoimmune hepatitis.

Hepatology (Baltimore, Md.)·2024

Same author

N-Acetylcysteine for the Management of Non-Acetaminophen Drug-Induced Liver Injury in Adults: A Systematic Review.

Frontiers in pharmacology·2022

Same author

A retrospective analysis of the duration of mechanical ventilation in Scandinavian paediatric heart centres.

Acta paediatrica (Oslo, Norway : 1992)·2022

Same author

Clinical characteristics of antiepileptic-induced liver injury in patients from the DILIN prospective study.

Journal of hepatology·2021

Same author

Effects of immunosuppressive drugs on COVID-19 severity in patients with autoimmune hepatitis.

Liver international : official journal of the International Association for the Study of the Liver·2021

Same author

Becoming an Expert by Experience: Benefits and Challenges of Educating Mental Health Nursing Students.

Issues in mental health nursing·2021

Search research articles

Related Experiment Video

Updated: Jul 13, 2026

A Model of Experimental Steatosis In Vitro: Hepatocyte Cell Culture in Lipid Overload-Conditioned Medium

A Model of Experimental Steatosis In Vitro: Hepatocyte Cell Culture in Lipid Overload-Conditioned Medium

Published on: May 18, 2021

Hepatitis C and steatosis.

Einar Björnsson¹, Paul Angulo

¹Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA.

Archives of Medical Research

|July 7, 2007

Summary

Hepatitis C infection and fatty liver disease often coexist. Managing weight may reduce liver fat and fibrosis, but its impact on antiviral treatment response requires further study.

Area of Science:

Hepatology
Virology
Metabolic Syndrome

Background:

Hepatitis C infection and non-alcohol-related hepatic steatosis are prevalent global liver diseases.
These conditions frequently co-occur, with Hepatitis C virus (HCV) genotype 3 directly causing steatosis, while insulin resistance drives steatosis in non-genotype 3 infections.
Insulin resistance, obesity, hyperglycemia, hypertriglyceridemia, hypertension, and low HDL are common in chronic hepatitis C.

Purpose of the Study:

To explore the distinct clinical and prognostic implications of liver steatosis in Hepatitis C virus (HCV) infection.
To review the role of insulin resistance and obesity in the development and progression of steatosis in HCV patients.
To assess the potential benefits of weight management on steatosis and fibrosis in the context of HCV infection.

More Related Videos

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Published on: March 11, 2017

Inducing and Characterizing Vesicular Steatosis in Differentiated HepaRG Cells

Inducing and Characterizing Vesicular Steatosis in Differentiated HepaRG Cells

Published on: July 18, 2019

Related Experiment Videos

Last Updated: Jul 13, 2026

A Model of Experimental Steatosis In Vitro: Hepatocyte Cell Culture in Lipid Overload-Conditioned Medium

A Model of Experimental Steatosis In Vitro: Hepatocyte Cell Culture in Lipid Overload-Conditioned Medium

Published on: May 18, 2021

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Published on: March 11, 2017

Inducing and Characterizing Vesicular Steatosis in Differentiated HepaRG Cells

Inducing and Characterizing Vesicular Steatosis in Differentiated HepaRG Cells

Published on: July 18, 2019

Main Methods:

Literature review and synthesis of existing evidence on HCV, hepatic steatosis, and insulin resistance.
Analysis of the impact of increased adiposity and steatosis on fibrosis progression and antiviral treatment response.
Evaluation of studies investigating weight management interventions in patients with HCV and steatosis.

Main Results:

HCV genotype 3 directly induces hepatic steatosis.
Insulin resistance is a key factor in steatosis development for non-genotype 3 chronic hepatitis C.
Increased adiposity and steatosis are linked to accelerated fibrosis progression and reduced response to antiviral therapy.

Conclusions:

Liver steatosis in HCV infection is a distinct entity with significant clinical and prognostic implications.
Weight management shows promise in reducing steatosis and improving fibrosis severity in HCV patients.
Further research is needed to confirm if weight reduction enhances response to antiviral therapy for Hepatitis C.